A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
NCT03697629
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma in Relapse
Interventions
DRUG:
Daratumumab
Sponsor
Canadian Myeloma Research Group